http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021188334-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d279ba91ffb8ef8f7ce3348e0803860 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 |
| filingDate | 2021-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02bbe076c6c53058bd742d35a4d5ddb7 |
| publicationDate | 2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021188334-A1 |
| titleOfInvention | Use of st266 to treat severe systemic inflammation and post-acute covid-19 syndrome |
| abstract | The invention is directed to methods for the treatment of severe systemic inflammatory responses, including but not limited to the severe systemic inflammatory response called a "cytokine storm". The invention is further directed to the use of ST266 to treat severe systemic inflammatory responses. Specifically, the invention is directed to methods for treating a cytokine storm or sequelae thereof by intravenously or intranasally administering ST266 to a subject suffering from such symptoms. |
| priorityDate | 2020-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 324.